

Title: ONCOLOGY EMERGENCY ESSENTIALS: Addressing Tumor Lysis Syndrome in Your Practice

Dates: 10/27/2017 – 10/27/2018

Locations: <https://reachmd.com/programs/cme/oncology-emergency-essentials-addressing-tumor-lysis-syndrome-in-your-practice/9814/>

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Recognize current, new, and emerging therapies that may place patients at risk for TLS
- Identify patients at risk for TLS who would benefit from close monitoring and/or early implementation of prophylactic measures
- Apply appropriate preventative and treatment strategies for hyperuricemia and TLS in cancer patients

Target Audience

Target audience includes hematologists-oncologists, nephrologists, cardiologists, emergency medicine physicians, internal medicine specialists, and oncology nurses

Program Overview

The goal of this program is to increase the knowledge and understanding of healthcare providers involved in the care of cancer patients at risk for tumor lysis syndrome (TLS). This interview with renowned expert, Dr. Mitchell Cairo, will follow on a comprehensive TLS risk classification system developed by an international TLS expert consensus panel.

Faculty

Mitchell S. Cairo, MD

Chief, Pediatric Hematology, Oncology and Stem Cell Transplantation
New York Medical College

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and Integritas. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement

Clinical and Patient Educators Association designates this enduring activity for a maximum of 0.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

CPEA requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support

This activity is supported by an independent educational grant from Sanofi US.